Strides Pharma Science Ltd · NSE:STAR
Strides Pharma Science — Q3 FY2023 Earnings Presentation
13 slides from Strides Pharma Science's earnings presentation, Jan 24, 2023
Slide 1: Q3FY23 Earnings Update
Q3FY23 Earnings Update Strides Pharma Science Limited January 24, 2023
Slide 2: Strides reports continued improvement in Q3FY23
Strides reports continued improvement in Q3FY23 Performance led by highest ever regulated markets revenues and margin expansion Quarterly Performance (₹m) Particulars Q3 FY23 Q2 FY23 Q3 FY22 QoQ YoY We are pleased to report continued momentum in our performance led by strong growth in the regulated
Slide 3: Strong performance in regulated markets business driven by growth across all key markets
Strong performance in regulated markets business driven by growth across all key markets Regulated markets business crosses the $100M mark for the first time in quarterly revenues ▸ US revenues at ₹5,072m ($63m) for Q3FY23, up from ₹4,726m ($60m) in Q2FY23 and ₹2,831m US business ($38m) in Q3FY22. M
Slide 4: Market Wise Outlook
Market Wise Outlook
Slide 5: US business continued the growth momentum with $63m revenues in Q3FY23
US business continued the growth momentum with $63m revenues in Q3FY23 US Revenues - Quarterly Trend ($ ₹/m) Quarterly Updates • Revenues from the US for Q3FY23 stood at ₹5,072m ($63m), up 7% QoQ and 79% YoY. 5,072 4,726 • US represented 58% of consolidated revenues for Q3FY23. 3,301 3,552 • Key pro
Slide 6: The Other Regulated Markets (ORM) returns to its historical growth trajectory
The Other Regulated Markets (ORM) returns to its historical growth trajectory Strong orderbook visibility to enable continuing growth across all key markets ORM Revenues - Quarterly Trend ($ ₹/m) Quarterly Updates • Revenues from the ORM for Q3FY23 stood at ₹3,138m ($39m), versus ₹2,414m ($31m) in 2
Slide 7: Brands business in Africa delivers steady performance
Brands business in Africa delivers steady performance Access markets business impacted due to lower offtake by donor funded agencies EM Revenues - Quarterly Trend ($ ₹/m) Quarterly Updates • Revenues from the Emerging and Access Markets for Q3FY23 stood at ₹475m ($6m), versus 2,858 ₹1,855m ($23m) in
Slide 8: Financial Performance
Financial Performance
Slide 9: Key P&L Highlights – Q3 FY23
Key P&L Highlights – Q3 FY23 Income statement (₹m) Particulars Q3 FY23 Q2 FY23 Q3 FY22 QoQ YoY Revenues 8,686 8,995 7,968 -3 % 9% EBITDA 1,201 1,006 40 19 % 100%+ EBITDA % 13.8 % 11.2 % 0.5% 260bps 1,330bps Reconciliation of EBITDA (₹m) As per SEBI results Q3 FY23 Q2 FY23 Q3 FY22 Profit before excep
Slide 10: Arrow transaction-related deferred consideration received during quarter end
Arrow transaction-related deferred consideration received during quarter end Proceeds to be used for debt reduction Strides had guided for a target Gross Debt reduction of ~ ₹10bn in FY23 (Constant currency basis) Dec’22 Mar’22 Particulars ₹m* ₹m Term Loans 13,707 12,997 Adjusting for Arrow deferred
Slide 11: Earnings Call Details
Earnings Call Details
Slide 12: Q3FY23 Earnings Call invitation
Strides Pharma Science Ltd – Q3FY23 Earnings Call invites you to interact with the senior management on Q3FY23 Click on the icon above to pre-register and join without the operator January 24 , 2023 4:30pm IST / 11:00am GMT / 6:00am EST / 7:00pm HKT Join through an operator using dial in numbers Ind
Slide 13: Thank You
Thank You Strides Pharma Science Limited CIN: L24230MH1990PLC057062 REGISTERED OFFICE 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924/ 2789 3199 Fax: +91 22 2789 2942 Email: corpcomm@strides.com Website: www.strides.com CORPORATE OFFICE Strides House, Bilekahalli
Strides Pharma Science — Q3 FY2023 Earnings Presentation on 6ix